Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10264193
• 负责人: GENE E ALEXANDER
• 金额: $ 97.36万
• 依托单位: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-05 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264193
• 关键词: Address; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid; Archives; Arizona; Behavioral; Biological; Biological Markers; Blood; Blood specimen; Brain; Brain imaging; Cerebrospinal Fluid; Clinical; Clinical Data; Cognitive; Collection; Communities; DNA; Data; Detection; Development; Diagnosis; Disease; Early Diagnosis; Elderly; Enrollment; Evaluation; Fostering; Funding; Genetic Risk; Goals; Grant; Image Analysis; Individual; Liquid substance; Longitudinal cohort; MRI Scans; Magnetic Resonance Imaging; Mission; Participant; Pathology; Peripheral Blood Mononuclear Cell; Plasma; Positron-Emission Tomography; Preparation; Prevention therapy; Prevention trial; Research; Research Personnel; Resource Sharing; Resources; Risk; Role; Sampling; Scanning; Specimen; Spottings; Standardization; Students; Technology; Training Support; Validation; Work; actigraphy; base; biomarker validation; blood-based biomarker; cohort; data analysis pipeline; design; digital; early detection biomarkers; end of life; follow-up; image processing; neuroimaging; neuropathology; pre-clinical; preclinical study; prevention evaluation; programs; research study; tau Proteins; training opportunity

PROJECT SUMMARY/ABSTRACT - BIOMARKER CORE The Biomarker Core (BC) will provide access across the Arizona ADRC to advance brain imaging, fluid, and wearable/digital biomarker expertise, resources, data, and specimens for application with our center and complementary affiliated cohorts to support NIA ADRC program goals. The Arizona ADRC has a major thematic focus on advancing efforts in the use of blood-based biomarkers (BBBs) in the diagnosis, preclinical study and prevention of AD. The BC will facilitate this thematic focus by supporting ADRC researchers in their efforts to: 1) further clarify the cognitive and biological changes associated with preclinical AD; 2) validate and clarify the role of new brain imaging, CSF, and blood-based biomarkers in the early detection and tracking of AD and to evaluate the potential of wearable/digital technologies as behavioral AD biomarkers; 3) inform the design, endpoints, and statistical power of prevention trials in individuals at different levels of AD risk to support our goal of finding effective AD prevention therapies; and 4) provide a valuable shared resource for Arizona ADRC researchers, the NIA ADRC program nationally, and researchers around the world studying AD and related disorders. To achieve these goals, the BC will support the standardized acquisition, processing, and analysis of amyloid PET, tau PET, and MRI; the standardized collection, preparation, storage, and analysis of blood, CSF, and DNA samples; and the acquisition, processing, and analysis of wearable/digital behavioral biomarkers in clinically well-characterized ADRC participants, many of whom have also agreed to brain donation. The BC will maintain a strong relationship with NCRAD for the processing and banking of blood and CSF samples and will fully support the NIA SCAN initiative for the sharing and archiving of ADRC BC neuroimaging scans with NACC. The BC will provide expertise and support to help ADRC researchers fully utilize the core resources and will work with each of the Arizona ADRC Cores, as well as investigators within and outside Arizona, to advance AD-related research. The BC will address the following specific aims: 1) to provide access to amyloid and tau PET, MRI scans, CSF and blood samples, and wearable/digital activity data across the Arizona ADRC; 2) to make available for research neuroimaging data, fluid specimens and biomarkers, and wearable/digital activity data from clinically well-characterized ADRC participants; 3) to support the development, evaluation, and implementation of blood-based biomarkers for early detection and tracking of AD risk and pathology; 4) to provide a resource of expertise and support for brain image processing and analysis for use in AD-related research studies; and 5) to foster collaborative research by working closely with each of the Arizona ADRC Cores, as well as users of these core resources inside and outside Arizona.

项目摘要/摘要 - 生物标志物核心 生物标志物核心（BC）将在整个亚利桑那州ADRC上提供访问，以推动大脑成像，流体和 可穿戴/数字生物标志物专业知识，资源，数据和标本，用于我们的中心和 互补的附属队员支持NIA ADRC计划目标。亚利桑那ADRC有一个专业 主题专注于在诊断中促进使用基于血液的生物标志物（BBB）的努力，临床前 研究和预防AD。卑诗省将通过支持ADRC的研究人员来促进这一主题重点 努力：1）进一步阐明与临床前AD相关的认知和生物学变化； 2）验证和 阐明新的脑成像，CSF和基于血液的生物标志物在早期检测和跟踪中的作用 广告并评估可穿戴/数字技术作为行为AD生物标志物的潜力； 3）告知 在不同级别的AD风险中，预防试验的设计，终点和统计能力以支持 我们找到有效的AD预防疗法的目标； 4）为亚利桑那州提供宝贵的共享资源 ADRC研究人员，NIA ADRC计划在全国范围内以及全球研究广告的研究人员 相关疾病。为了实现这些目标，卑诗省将支持标准化的收购，处理和 分析淀粉样蛋白宠物，tau宠物和MRI；标准化的收集，准备，存储和分析 血液，CSF和DNA样品；以及可穿戴/数字行为的获取，处理和分析 临床表征良好的ADRC参与者中的生物标志物，其中许多人也同意大脑 捐款。卑诗省将与NCRAD保持牢固的关系，以处理和依靠血液的处理和押金 CSF样品，并将充分支持NIA扫描计划，以共享和归档ADRC BC NACC神经影像学扫描。卑诗省将提供专业知识和支持，以帮助ADRC的研究人员充分 利用核心资源，并将与每个亚利桑那ADRC核心一起工作，以及内部的调查人员 以及亚利桑那州以外的地区，以推进与广告相关的研究。卑诗省将解决以下特定目标：1） 提供淀粉样蛋白和tau宠物，MRI扫描，CSF和血液样本以及可穿戴/数字活动数据 在亚利桑那州的ADRC中； 2）可用于研究神经影像学数据，流体标本和 来自临床表征良好的ADRC参与者的生物标志物以及可穿戴/数字活动数据； 3）到 支持基于血液的生物标志物的开发，评估和实施，以提早检测 跟踪AD风险和病理； 4）为大脑图像处理提供专业知识和支持资源 和用于广告相关研究的分析； 5）通过紧密工作来促进协作研究 亚利桑那州ADRC核心以及亚利桑那州内外这些核心资源的用户都有每个。